Alice Goodman

Authored Items

Pertuzumab a New Therapeutic Option for Patients with HER2-Positive Metastatic Breast Cancer

October 2012, Vol 3, No 7 - Drug Updates

Breast cancer is the most common cancer and the second leading cause of cancer death among women worldwide.1 In the United States, an estimated 230,480 new cases of invasive breast cancer, as well as an additional 57,650 cases of carcinoma in situ, were expected to be diagnosed in 2011. Approximately 39,500 deaths from breast cancer were expected to occur in 2011.2

[ Read More ]

A Rational Step in Holding Down Costs in Cancer Care

November 2012, Vol 3, No 8 - Economics of Cancer Care

?The cost of cancer care matters; in fact, it matters so much that Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City has decided not to include in its formulary the newly approved drug ziv-aflibercept (Zaltrap), which was re­­cently approved for use in patients with progressive metastatic colorectal cancer. The decision is based on considering cost versus benefit rather than on “newer is better.”

[ Read More ]

Ponatinib Given Early May Suppress New Mutations in Patients with CML

September 2013, Vol 4, No 7 - Personalized Medicine

Chicago, IL—A new analysis of mutations at baseline and at the end of treatment provides information about the response to ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphocytic leukemia (ALL) enrolled in the phase 2 PACE study. The results were presented at the 2013 annual meeting of the American Society of Clinical Oncology.

[ Read More ]

High Marks for Nutritional Supplement in Patients with Localized Prostate Cancer

September 2013, Vol 4, No 7 - Cancer Prevention

Berlin, Germany—A food supplement containing pomegranate seeds, green tea, broccoli, and turmeric—called Pomi-T (natureMedical)—taken twice daily significantly lowered prostate-specific antigen (PSA) levels versus placebo in men with localized prostate cancer, according to the results of a double-blind, placebo-controlled clinical trial. Use of the supplement allowed more men to remain on observation alone, according to results of a new study presented at the 2013 meeting of the Multinational Association of Supportive Care in Cancer.

[ Read More ]

Including Caregivers in the Care of Patients with Cancer Improves Quality of Life

September 2013, Vol 4, No 7 - Survivorship

Washington, DC—Real-life experience translated into a research interest for Fedricker D. Barber, RN, MSN, of the M.D. Anderson Cancer Center, Houston, TX. At the 38th Annual Congress of the Oncology Nursing Society, Ms Barber presented a poster about the relationships between adult cancer survivors’ and caregivers’ social support, self-efficacy for physical activity, and quality-of-life (QOL) issues.

[ Read More ]

QOL Improved with 18 versus 36 Months of Hormonal Therapy in Patients with High-Risk Prostate Cancer, Confirming Earlier Efficacy Evidence

March 2014, Vol 5, No 2 - Prostate Cancer

San Francisco, CA—Longer-term follow-up of a large randomized phase 3 trial suggests that quality of life (QOL) is improved when patients with high-risk prostate cancer have a shorter versus longer course of androgen- deprivation therapy (ADT) plus radiotherapy as primary treatment. In this follow-up study, 18 months of ADT were found to improve QOL versus 36 months of ADT when added to radiotherapy. [ Read More ]

New Guidelines Expand Pool of Patients Eligible for Sentinel Node Biopsy

May 2014, Vol 5, No 4 - Breast Cancer

The American Society of Clinical Oncology (ASCO) has issued new guidelines for the use of sentinel node biopsy (SNB) in patients with early-stage breast cancer (Lyman GH, et al. J Clin Oncol. 2014;32:1365-1383. The newer version expands the use of SNB to a larger group of patients, based on evidence from 9 randomized trials and 13 cohort studies conducted since 2005, when the first SNB guidelines were published. [ Read More ]

Lowering Dietary Fat Increases Long-Term Survival in Women with Hormone-Negative Breast Cancer

March 2015, Vol 6, No 2 - Breast Cancer

San Antonio, TX—Results of a new nutrition study show that women who reduced their intake of dietary fat for 5 years after being diagnosed with early breast cancer had significantly lower rates of death from all causes compared with controls, at 15 years of follow-up; this reduction was seen specifically in women with hormone receptor (HR)-­negative breast cancer. No long-term effect of dietary fat reduction on mortality was observed in women with HR-positive breast cancer. The results of the study, called Women’s Intervention Nutrition Study (WINS), were presented at the 2014 San Antonio Breast Cancer Symposium. [ Read More ]

Millions in Savings by Using Prolaris Test in All Men with Localized Prostate Cancer

April 2015, Vol 6, No 3 - Economics of Cancer Care

Orlando, FL—Significant cost-savings in treating patients with prostate cancer could be achieved in the US healthcare system with the use of the cell-cycle progression (CCP) gene-expression assay called Prolaris (from Myriad Genetics Laboratories), according to a poster from E. David Crawford, MD, Professor of Surgery and Radiation Oncology, University of Colorado, Aurora, and colleagues, presented at the 2015 Genitourinary Cancers Symposium. [ Read More ]

Clinical Utility of Genomic Biomarker Tests Questioned

April 2015, Vol 6, No 3 - Personalized Medicine

Orlando, FL—An independent review of the literature suggests that 3 biomarker tests developed for prostate cancer have yet to justify their utility in randomized clinical trials. The 3 tests in question—Prolaris, Decipher, and Oncotype DX for prostate cancer—are being used in practices around the country, cost approximately $3500 per test, and are reimbursable by Medicare depending on the state. [ Read More ]

Molecular Signature for Neuroendocrine Prostate Cancer Represents Progress

September 2015, Vol 6, No 8 - Personalized Medicine

Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations. [ Read More ]

“Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation

September 2015, Vol 6, No 8 - Emerging Therapies

Boston, MA—Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs. [ Read More ]

SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer

September 2015, Vol 6, No 8 - Thyroid Cancer

Chicago, IL—Lenvatinib (Lenvima) was approved by the FDA in February 2015 for the treatment of patients with advanced radioactive iodine (131I)-­refractory differentiated thyroid cancer based on the SELECT trial results. Investigators looked at which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At the 2015 American Society of Clinical Oncology meeting, 2 subgroup analyses of SELECT shed light on patient selection for treatment with lenvatinib. [ Read More ]

Controlled Ovarian Hyperstimulation Safe in Patients with Breast Cancer

September 2015, Vol 6, No 8 - Breast Cancer

Boston, MA—Fertility preservation by controlled ovarian hyperstimulation with concurrent letrozole (Femara) is safe in women with breast cancer, according to a single-center, prospective study on the long-term safety of fertility preservation by the use of ovarian stimulation and concurrent aromatase inhibitors in women with breast cancer, presented at the 2015 Best of ASCO meeting in Boston. Controlled ovarian hyperstimulation had no impact on relapse-free survival and enabled live births in a substantial proportion of women who later chose to retrieve their frozen embryos or oocytes. [ Read More ]

Gene-Expression Signature Validated as Prognostic Marker in Stage II Colon Cancer

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Personalized Medicine

A gene-expression signature assay called ColDx (Almac Diagnostics) successfully identified high-risk patients with stage II colon cancer who would benefit from chemotherapy, according to results of a new, prospective analysis of the previously published phase 3 Alliance C9581 clinical trial. For patients with stage I colon cancer, surgery is the treatment of choice, whereas for stage III disease, patients receive adjuvant chemotherapy. For patients with stage II disease, however, the best approach to the therapy has not been well-defined.

[ Read More ]

Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Prostate Cancer

The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet. 2016 Jul 26. Epub ahead of print). The 24-month results will be published at a later time.

[ Read More ]

Collaborative Oncology Care Requires Good Mentoring, Self-Study

September 2016, Vol 7, No 8 - Collaborative Care

Collaborative oncology care, which involves incorporating an advanced practitioner (AP) into an oncology practice, will help meet the growing burden of complex care and improve patient satisfaction. Collaborative care is also cost-effective, and oncologists report increased professional satisfaction when an AP is part of their practice, said Wendy H. Vogel, MSN, FNP, AOCNP, Wellmont Cancer Institute, Kingsport, TN, at the 2016 American Society of Clinical Oncology (ASCO) annual meeting. Ms Vogel discussed the role of the AP in providing advanced oncology care to the community. [ Read More ]

Gene Signature May Identify Nonresponders to Nivolumab

September 2016, Vol 7, No 8 - Personalized Medicine

Immunotherapies have changed the way many patients with cancers, including patients with renal-cell carcinoma (RCC), are treated. Although some patients have a dramatic response to immunotherapies that appears to be sustained over the long-term, a large proportion of patients do not respond to treatment with programmed death (PD)-1 or PD ligand 1 (PD-L1) inhibitors. Therefore, the search continues for biomarkers that can help to determine which patients will likely respond to available checkpoint inhibitors, optimizing treatment selection. [ Read More ]